Avedro, Inc.   Report issue

For profit Phase 3 Phase 4
Founded: Cambridge Massachusetts United States (2009)
Status: Acquired by Glaukos Corporation (2019)

Organization Overview

First Clinical Trial
2009
NCT00674661
First Marketed Drug
2016
riboflavin
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Avedro, Inc. | AVEDRO INC